These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35577099)

  • 1. Decrypting the mechanistic basis of CRISPR/Cas9 protein.
    Panda G; Ray A
    Prog Biophys Mol Biol; 2022 Aug; 172():60-76. PubMed ID: 35577099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. sgRNA Sequence Motifs Blocking Efficient CRISPR/Cas9-Mediated Gene Editing.
    Graf R; Li X; Chu VT; Rajewsky K
    Cell Rep; 2019 Jan; 26(5):1098-1103.e3. PubMed ID: 30699341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The initiation, propagation and dynamics of CRISPR-SpyCas9 R-loop complex.
    Zeng Y; Cui Y; Zhang Y; Zhang Y; Liang M; Chen H; Lan J; Song G; Lou J
    Nucleic Acids Res; 2018 Jan; 46(1):350-361. PubMed ID: 29145633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single molecule methods for studying CRISPR Cas9-induced DNA unwinding.
    Okafor IC; Choi J; Ha T
    Methods; 2022 Aug; 204():319-326. PubMed ID: 34767923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the Thermodynamic Landscape of CRISPR/Cas9: Insights into Enhancing Gene Editing Precision and Efficiency.
    Kumar A; Daripa P; Rasool K; Chakraborty D; Jain N; Maiti S
    J Phys Chem B; 2024 Sep; 128(35):8409-8422. PubMed ID: 39190773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
    Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
    PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Points of View on the Tools for Genome/Gene Editing.
    Chuang CK; Lin WM
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridge Helix of Cas9 Modulates Target DNA Cleavage and Mismatch Tolerance.
    Babu K; Amrani N; Jiang W; Yogesha SD; Nguyen R; Qin PZ; Rajan R
    Biochemistry; 2019 Apr; 58(14):1905-1917. PubMed ID: 30916546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phage AcrIIA2 DNA Mimicry: Structural Basis of the CRISPR and Anti-CRISPR Arms Race.
    Liu L; Yin M; Wang M; Wang Y
    Mol Cell; 2019 Feb; 73(3):611-620.e3. PubMed ID: 30606466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
    Zheng W
    Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
    Basila M; Kelley ML; Smith AVB
    PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulating CRISPR/Cas9 Function through Conditional Guide RNA Control.
    Brown W; Zhou W; Deiters A
    Chembiochem; 2021 Jan; 22(1):63-72. PubMed ID: 32833316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction and Validation of Native and Engineered Cas9 Guide Sequences.
    Briner AE; Henriksen ED; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pipeline for characterization of novel Cas9 orthologs.
    Karvelis T; Young JK; Siksnys V
    Methods Enzymol; 2019; 616():219-240. PubMed ID: 30691644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
    Edraki A; Mir A; Ibraheim R; Gainetdinov I; Yoon Y; Song CQ; Cao Y; Gallant J; Xue W; Rivera-Pérez JA; Sontheimer EJ
    Mol Cell; 2019 Feb; 73(4):714-726.e4. PubMed ID: 30581144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAs.
    Kundert K; Lucas JE; Watters KE; Fellmann C; Ng AH; Heineike BM; Fitzsimmons CM; Oakes BL; Qu J; Prasad N; Rosenberg OS; Savage DF; El-Samad H; Doudna JA; Kortemme T
    Nat Commun; 2019 May; 10(1):2127. PubMed ID: 31073154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
    Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
    Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleavage of DNA Substrate Containing Nucleotide Mismatch in the Complementary Region to sgRNA by Cas9 Endonuclease: Thermodynamic and Structural Features.
    Baranova SV; Zhdanova PV; Koveshnikova AD; Pestryakov PE; Vokhtantsev IP; Chernonosov AA; Koval VV
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting back malaria: CRISPR/Cas9 genome editing of Plasmodium.
    Lee MCS; Lindner SE; Lopez-Rubio JJ; Llinás M
    Brief Funct Genomics; 2019 Sep; 18(5):281-289. PubMed ID: 31365053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.